Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Clinical Trial of Hydroxyflutamide (Liproca Depot) in localized Prostate Cancer within the intermediate risk group

Trial Profile

A Phase III Clinical Trial of Hydroxyflutamide (Liproca Depot) in localized Prostate Cancer within the intermediate risk group

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 18 May 2020 According to a LIDDS media release, this study can be sufficient for a future registration of Liproca Depot, provided positive results.
    • 18 May 2020 According to a LIDDS media release, the company has received positive responses from the Swedish Medical Products Agency (MPA) regarding the proposed design for this study.
    • 07 Nov 2019 According to a LIDDS media release, this phase III clinical trial will be conducted in urology clinics in China and will be fully financed by the Jiangxi Puheng Pharma.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top